Clinical Edge Journal Scan

Early autologous fat grafting associated with increased BC recurrence risk


 

Key clinical point: Autologous fat grafting (AFG) in the second stage of a 2-stage prosthetic breast reconstruction was linked to a higher risk for breast cancer (BC) recurrence when performed within a year after mastectomy.

Major finding: Patients who did vs did not undergo AFG within 1 year after the primary operation had a significantly increased risk for disease recurrence (hazard ratio 5.701; 95% CI 1.164-27.927). However, delaying the fat grafting beyond 12 months after mastectomy did not affect survival outcomes.

Study details: Findings are from a retrospective cohort study including 267 patients with unilateral invasive BC who underwent total mastectomy and immediate tissue-expander-based reconstruction, of which 203 patients underwent the second-stage operation within 12 months of mastectomy and 64 patients underwent the operation after 12 months of mastectomy.

Disclosures: This study did not report the source of funding. The authors declared no conflicts of interest.

Source: Lee KT et al. Association of fat graft with breast cancer recurrence in implant-based reconstruction: Does the timing matter? Ann Surg Oncol. 2022;30(2):1087-1097 (Dec 10). Doi: 10.1245/s10434-022-12389-0

Recommended Reading

Commentary: New Drugs, and Exercise, in Breast Cancer January 2023
Breast Cancer ICYMI
Cancer clinics begin to accommodate patients demanding new cancer detection tests
Breast Cancer ICYMI
People with cancer should be wary of taking dietary supplements
Breast Cancer ICYMI
Contralateral BC risk elevated in women with germline pathogenic variants
Breast Cancer ICYMI
Adding veliparib to cisplatin improves PFS in BRCA-like metastatic TNBC
Breast Cancer ICYMI
ER/PgR+ BC: Adjuvant exemestane+ovarian suppression reduces recurrence risk
Breast Cancer ICYMI
Addition of atezolizumab to carboplatin+paclitaxel improves pCR in stage II-III TNBC
Breast Cancer ICYMI
ERBB2 mRNA expression predicts prognosis in trastuzumab emtansine-treated advanced HER2+ BC patients
Breast Cancer ICYMI
Overall survival improved with chemotherapy in ER-negative/HER2-negative, T1abN0 BC
Breast Cancer ICYMI
Meta-analysis compares adjuvant chemotherapy regimens for resected early-stage TNBC
Breast Cancer ICYMI